{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:22:31Z","timestamp":1794068551471,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jhep.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T12:04:57Z","timestamp":1715256297000},"page":"621-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-0480","authenticated-orcid":false,"given":"Heiner","family":"Wedemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-4870","authenticated-orcid":false,"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-5194","authenticated-orcid":false,"given":"Antje","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Bogomolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Chulanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mamonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5920-5703","authenticated-orcid":false,"given":"Natalia","family":"Geyvandova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viacheslav","family":"Morozov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-7342","authenticated-orcid":false,"given":"Olga","family":"Sagalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-4290","authenticated-orcid":false,"given":"Annemarie","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3873-096X","authenticated-orcid":false,"given":"Dmitry","family":"Manuilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-6732","authenticated-orcid":false,"given":"Renee-Claude","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben L.","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2616-3544","authenticated-orcid":false,"given":"Grace M.","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Osinusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Schulze zur Wiesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.05.001_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","article-title":"Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options","volume":"13","author":"Lempp","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104812","article-title":"Current knowledge on hepatitis delta virus replication","volume":"179","author":"Lucifora","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2024.05.001_bib4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/141.5.590","article-title":"Transmission of the hepatitis B virus-associated delta antigen to chimpanzees","volume":"141","author":"Rizzetto","year":"1980","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2024.05.001_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.05.001_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatitis D","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.05.001_bib9","article-title":"Hepatitis D virus infection: pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022","volume":"5","author":"Lampertico","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.05.001_bib10","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2024.05.001_bib11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.05.001_bib12","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s12072-023-10575-0","article-title":"Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection","volume":"17","author":"Wranke","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.05.001_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.05.001_bib15","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2024.05.001_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.15410","article-title":"Interferon-based treatment of chronic hepatitis D","volume":"43","author":"Sandmann","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.05.001_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2024.05.001_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2024.05.001_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.001_bib21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.05.001_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2024.05.001_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2024.05.001_bib24","article-title":"Summary of product characteristics","year":"2021","journal-title":"Gilead Sci Ireland UC"},{"key":"10.1016\/j.jhep.2024.05.001_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib26","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib27","first-page":"S26","article-title":"Bulevirtide, with or without peg-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program","author":"De Ledinghen","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.001_bib28","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S0168-8278(23)00593-7","article-title":"Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy: the retrospective multicenter European study (Save-D)","volume":"78","author":"Degasperi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib29","article-title":"Treating hepatitis D with bulevirtide - real-world experience from 114 patients","volume":"5","author":"Dietz-Fricke","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.05.001_bib30","article-title":"Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression","volume":"5","author":"Jachs","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.05.001_bib31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFNalpha for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib32","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2023.04.027","article-title":"No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta","volume":"79","author":"Hollnberger","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib34","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.05.001_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor myrcludex B: effects on bile acid disposition and tenofovir pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.05.001_bib36","doi-asserted-by":"crossref","first-page":"100893","DOI":"10.1016\/j.jhepr.2023.100893","article-title":"Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV\/HDV","volume":"5","author":"Mateo","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.05.001_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)00540-2","article-title":"Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort","volume":"77","author":"Fontaine","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.05.001_bib39","series-title":"Poster presented at: American Association for the Study of Liver Diseases: The Liver Meeting; Boston, MA","article-title":"Efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: primary endpoint results from a phase 2b open-label, randomized, multicenter study MYR204","author":"Asselah","year":"2023"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2026.05.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000}},{"DOI":"10.1016\/j.jhep.2026.05.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824003337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824003337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:38:19Z","timestamp":1773967099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824003337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0168827824003337"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.05.001","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}